

INSIDE THIS ISSUE:

- 1 Meet our President & CEO
- 1 Social Media
- 1 Actinium-225
- 2 Tc-99m Generator
- 2 CNSC Annual Public Meeting
- 2 About Us

TALK TO US

We Want to Hear From You!

Please reach out to us if you have any questions about our operations!

PHONE: **1.833.657.4565**
EMAIL: IsotopeQuestions@bwxt.com
ONLINE: medical.bwxt.com

**447 March Road,
Ottawa, ON, K2K 1X8**

Meet Dr. Cirtain, BWXT Medical President & CEO

We are excited to announce that Dr. Jonathan Cirtain was recently appointed as BWXT Medical's President & CEO. Dr. Cirtain joined BWXT Medical's parent company, BWXT, as Director of Commercial Technologies in 2017.

Dr. Cirtain later served as President of BWXT Advanced Technologies LLC, where he oversaw the company's entrance to the nuclear medicine industry through the development of BWXT's Tc-99m technology. Before joining BWXT, Jonathan spent nine years with NASA where he held positions of increasing responsibility from astrophysicist to the Science Research Office manager.


He also co-founded Astraea, Inc., a machine learning and data science analytics company.



Dr. Jonathan Cirtain,
BWXT Medical's President & CEO

BWXT Medical completes first radiochemical production of Actinium-225

BWXT Medical is proud to have recently completed its first radiochemical production of Actinium-225 (Ac-225) at its Vancouver facility – a developmental isotope that is used in cutting edge cancer research! Ac-225 is a highly powerful radioisotope, which is attached to specific tumor-seeking biomolecules that treat cancer directly while limiting damage to healthy cells. Learn more by visiting our website under News: medical.bwxt.com



BWXT Medical Submits Tc-99m Generator New Drug Application to FDA

On September 13th, BWXT Medical announced it had submitted a new drug application to the U.S. Food and Drug Administration (FDA) to request approval of its technetium-99m (Tc-99m) generator for diagnostic imaging.

Once approved for commercial production by regulatory bodies, BWXT Medical's new proprietary manufacturing technology will be used to irradiate molybdenum targets at an Ontario Power Generation reactor, process Mo-99 (the parent isotope of Tc-99m) and subsequently incorporate material into Tc-99m generators at BWXT Medical's Kanata, Ontario facility for delivery to radiopharmacies and hospitals across the United States and Canada.

Tc-99m is used in over 40 million diagnostic procedures annually, and is the daughter isotope of molybdenum-99

(Mo-99). Historically Mo-99 has been produced within research reactors using uranium as a starting material. Alternatively, the BWXT Tc-99m generator will be produced from natural molybdenum targets irradiated at a commercial power reactor, greatly reducing complex waste by-products. These targets are processed into the finished active pharmaceutical ingredient and then loaded into generators that have the function and form of generators already used at radiopharmacies and hospitals today.



Learn more by visiting our website at: medical.bwxt.com

CNSC Annual Public Meeting

BWXT Medical and other licensees will participate in a virtual public meeting on December 16, 2022 held by Canada's nuclear regulator, the Canadian Nuclear Safety Commission (CNSC).



Each year, BWXT Medical submits an Annual Compliance Report (ACR) to the CNSC with the purpose of demonstrating that BWXT Medical has successfully met the requirements of the Nuclear Safety and Control Act for its Class IB Nuclear Substance Processing Facility Operating Licence.

BWXT Medical's 2021 ACR can be found on our website at medical.bwxt.com.

At the meeting, CNSC Staff will present their annual Regulatory Oversight Report. The Report is available on the CNSC's website at: nuclearsafety.gc.ca.

We're Hiring!

Looking for a new opportunity? Join our team!

Working for BWXT Medical means being part of a team focused on safety, technology, innovation and operational excellence. Visit our website at www.bwxt.com/careers

ABOUT US

In April 2018, BWXT announced a ground-breaking technology poised to make a significant, positive impact on the supply reliability of the North American nuclear medicine market. To develop and commercialize this technology, in July 2018, BWXT acquired Sotera Health's Nordion Medical Isotopes division. Combining the power of innovative technology for Technetium-99m generators and the expertise of an established leader in the nuclear medicine industry formed the foundation of BWXT's nuclear medicine business - BWXT Medical. BWXT's strategic acquisition adds 40 years of industry experience and a world-class product line to our existing capabilities and intellectual property. With our company at the forefront of medical isotope and radiopharmaceutical production, the quality products, high-level service and unwavering commitment that we have previously provided to our customer base will remain unchanged.



Headquartered in Ottawa, Ontario, BWXT Medical Ltd. employs over 250 highly-skilled professionals across both Ottawa and Vancouver, British Columbia. We manufacture custom radiopharmaceuticals, radiotherapies and medical isotopes in our 80,000 ft² cGMP manufacturing facility in Ottawa and at the state-of-the-art commercial cyclotron facility within TRIUMF, Canada's particle acceleration centre, in Vancouver.

